| Entry |
|
|---|
| Name |
Cyclophosphamide (USP);
Cyclophosphamide hydrate (JP17);
Cytoxan (TN);
Neosar (TN)
|
|---|
| Product |
|
|---|
| Generic |
CYCLOPHOSPHAMIDE (ANI Pharmaceuticals), CYCLOPHOSPHAMIDE (ANI Pharmaceuticals), CYCLOPHOSPHAMIDE (Amneal Pharmaceuticals LLC), CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation), CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation), CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation), CYCLOPHOSPHAMIDE (Baxter Healthcare Corporation), CYCLOPHOSPHAMIDE (BluePoint Laboratories), CYCLOPHOSPHAMIDE (Cipla USA), CYCLOPHOSPHAMIDE (NorthStar Rx LLC), CYCLOPHOSPHAMIDE (NorthStar RxLLC), CYCLOPHOSPHAMIDE (STI Pharma LLC), CYCLOPHOSPHAMIDE (Sandoz) |
|---|
| Formula |
C7H15Cl2N2O2P. H2O
|
|---|
| Exact mass |
278.0354
|
|---|
| Mol weight |
279.1012
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
|
|---|
| Remark |
| Therapeutic category: | 4211 |
| Product (DG00675): | D00287<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Alkylating agent, Immunosuppressant |
|---|
| Disease |
Hodgkin's disease [DS: H00007] Burkitt lymphoma [DS: H00008] Multiple myeloma [DS: H00010] Chronic lymphocytic leukemia [DS: H00005] Acute myelogenous leukemia [DS: H00003] Acute lymphoblastic (stem-cell) leukemia [DS: H00001 H00002] Mycosis fungoides [DS: H01463] Neuroblastoma [DS: H00043] Adenocarcinoma of the ovary [DS: H00027] Retinoblastoma [DS: H01513] Carcinoma of the breast [DS: H00031] Nephrotic syndrome [DS: H01657] |
|---|
| Comment |
Active form of prodrug: 4-Hydroxycyclophosphamide [CPD: C07643]
|
|---|
| Target |
DNA |
|---|
| Metabolism |
Enzyme: CYP2B6 [HSA: 1555]; CYP2A6 [HSA: 1548], CYP2C8 [HSA: 1558], CYP2C9 [HSA: 1559], CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07040 | Antineoplastics - alkylating agents |
| map07050 | Antirheumatics - DMARDs and biological agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01A ALKYLATING AGENTS
L01AA Nitrogen mustard analogues
L01AA01 Cyclophosphamide
D00287 Cyclophosphamide (USP) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Alkylating Agents
Cyclophosphamide
D00287 Cyclophosphamide (USP)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
421 Alkylating agents
4211 Chlorethylamines
D00287 Cyclophosphamide (USP); Cyclophosphamide hydrate (JP17)
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00287 Cyclophosphamide hydrate
D00287 Cyclophosphamide tablets
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00287
Prodrugs [br08324.html]
DG00675
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 15
1 P1a P 22.9658 -14.9801
2 N1c N 22.9715 -13.5156
3 N1x N 24.0976 -15.6395
4 O2x O 21.8279 -15.6395
5 O3b O 21.6997 -14.2450
6 C1b C 21.6646 -12.8388
7 C1b C 24.2027 -12.7220
8 C1x C 24.0976 -16.9523
9 C1x C 21.8279 -16.9523
10 C1b C 20.4335 -13.6264
11 C1b C 25.5096 -13.3990
12 C1x C 22.9658 -17.5999
13 X Cl 19.1265 -12.9613
14 X Cl 26.7467 -12.6054
15 O0 O 27.7975 -15.3471
BOND 14
1 1 2 1
2 1 3 1
3 1 4 1
4 1 5 2
5 2 6 1
6 2 7 1
7 3 8 1
8 4 9 1
9 6 10 1
10 7 11 1
11 8 12 1
12 10 13 1
13 11 14 1
14 9 12 1
|
|---|
